Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Pharmactive: Carob Extract Helps Restore Syndrome X Cardiometabolic Alterations


News provided by

Pharmactive Biotech Products, S.L.U.

22 Nov, 2022, 12:00 GMT

Share this article

Share toX

Share this article

Share toX

Study suggests Pharmactive's CSAT+® carob extract, plus aerobic exercise and balanced diet, help ameliorate cardiometabolic dysfunction impaired by Metabolic Syndrome

MADRID, Nov. 22, 2022 /PRNewswire/ -- Supplementation with the proprietary carob seed and pod extract CSAT+®, by Pharmactive Bioactive Products, SLU, combined with a low-calorie diet and aerobic training, could help reverse some of the cardiometabolic alterations associated with Metabolic Syndrome, according to results of a new animal study.

Continue Reading
This image opens in the lightbox
Pharmactive: Carob Extract Helps Restore Syndrome X Cardiometabolic Alterations

Metabolic Syndrome (MetS), also known as Syndrome X, is characterized by a cluster of risk factors, such as high triglycerides, unbalanced cholesterol levels, abdominal obesity, insulin resistance, and high blood pressure. These are known to predispose development of metabolic and cardiovascular diseases, such as Type 2 diabetes and heart disease, among other complications. Development of MetS is strongly correlated to Western diets and lack of regular physical exercise. A wide pool of scientific literature assumes that a combination of low grade of chronic inflammation and oxidative stress underpin the development of insulin resistance and the cascade of MetS-induced complications.

The in vivo study[1], published in the September 2022 issue of Antioxidants, was led by Maria de la Fuente–Fernández, PhD, at the Autonomous University of Madrid. The goal was to investigate whether supplementation with Pharmactive's CSAT+, alone or in combination with aerobic training, accelerates the restoration of cardiometabolic health in caloric-restricted mice with MetS.

Both caloric reduction and aerobic training improved lipid profile, vascular tone, and attenuated MetS–induced insulin resistance. However, only supplementation with CSAT+® enhanced body weight loss, increased the circulating levels of adiponectin (known to regulate blood glucose levels), and lowered a range of pro-inflammatory markers, specifically IL–6 and TNF.

At the same time, it increased gene expression of antioxidant enzymes. CSAT+® supplementation also reduced abdominal fat tissue, improved insulin sensitivity in the liver and skeletal muscle, and reduced obesity–induced hypertension for a more enduring effect. It is believed that the positive effect of CSAT+ on body weight loss is mostly attributed to its satiating effect, since obese mice supplemented with the carob extract showed decreased food intake compared to non–supplemented mice.

The study was a follow up to a 2020 study in which CSAT+ was found to act as an effective preventative against the development of cardiometabolic alterations when administered during the fattening period to mice developing MetS. "The recent study was designed to assess the possible beneficial role of CSAT+ once MetS is has been already established," explains Daniel Gonzalez-Hedström, Ph.D., Senior Scientific Researcher for Pharmactive. "We also wanted to analyze if supplementation with CSAT+ in combination with aerobic training could offer any synergistic benefit in accentuating the weight-reducing effect and improve metabolic and cardiovascular function in obese mice. CSAT alone had no impact on weight loss in conjunction with a high sugar and fat diet, which also supports the importance of maintaining a balanced diet and lifestyle to cardiovascular health."

"The ancient carob fruit contains several phenolic compounds in the pulp with antioxidant capacity, and with more potent concentrations in the pods and seeds," adds Carlos Rodriguez, Head of Marketing for Pharmactive. "The perceived beneficial effect of CSAT+ supplementation on weight loss, improved lipid profile, insulin sensitivity, and blood pressure is likely attributed to its powerful anti-inflammatory and antioxidant properties."

The carob pod native, to the Mediterranean, was historically consumed as a naturally sweet energetic snack and has been long extolled as a highly nutritious food. It contains an impressive array of bioactive compounds charged with natural abilities to optimize metabolism. These include dietary fibers, bioactive polysaccharides (specifically galactomannan and oligofructose), polyphenols (such as gallic acid), as well as amino acids and minerals (especially calcium, potassium, and iron).

Standardized to at least 36% galactomannans, 2% oligofructose, and 1% polyphenols, CSAT+ carob extract is grown in Spain. The 100% soluble powder complex is suitable for dietary supplements or integration into a range of functional foods and beverages. A minimum daily dosage of 300mg of CSAT+ is recommended for weight control, with 1000 mg daily recommended for maximum efficacy.

Visit us at Fi Europe in Paris, on December 6-8, Booth 7.2G63

About Pharmactive Biotech Products, S.L.U.

Pharmactive Biotech Products, S.L.U., is a privately-owned company that develops, and manufactures differentiated natural ingredients supported by scientific evidence. The company was founded by a group of entrepreneurs led by Jean-Marie Raymond, who developed a breakthrough concept for the traditional Mediterranean plant of saffron. With high standards and dedicated R&D investment, Pharmactive was the first company to introduce saffron extract for mood improvement. Pharmactive partners internationally with universities and research organizations to boost its R&D capabilities and generate new opportunities for its customers.

For more information, contact:

Company Contact:

Press Contact:

Pharmactive Biotech Products, S.L.

NutriPR

Carlos Rodriguez

Communication Manager

Tel: +34 635 785 984

Email: carlos.rodriguez@pharmactive.eu             

Liat Simha

Tel: +972-9-9742893

E-mail: liat@nutripr.com

Twitter: @NutriPR_

Twitter: @Pharmactive_SP

Web: www.pharmactive.eu

Web: www.nutripr.com

 

[1] https://pharmactive.eu/wp-content/uploads/2022/11/CSAT_Study_Metabolic_syndrome_MariaDeLaFuente_2020.pdf

Photo: https://mma.prnewswire.com/media/1953492/Pharmactive_Carob_Extract.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.